
NAPLEX - Osteoporosis



Across

- 3. Carries a black box warning for osteosarcoma
- **6.** Lower efficacy than first-line agents, may be beneficial for breast cancer, and increases the risk for DVT/stroke
- 10. Monoclonal antibody that targets RANKL and prevents activating RANK which is important in activating the action of osteoclasts; thus reducing bone resorption and increasing bone strength (brand name)
- **11.** Brand name bisphosphonate that has an IV and oral formulation
- **12.** Scoring system that includes clinical risk factors and is used to determine if a patient should begin osteoporosis therapy
- **13.** Stimulates estrogen receptors selectively in bone tissue leading to an increase in bone strength (brand name)
- **16.** Abbreviation for potential complication in patients taking zoledronic acid

Down

- 1. Brand name medication that has anabolic (bone-building) effects by stimulating osteoblasts
- **2.** Class of medication that is most often used first-line for osteoporosis
- **4.** Beneficial for osteoporosis but avoided due to the risk of cancer and blood clots
- **5.** Scan that assesses bone mineral density
- 7. Potential toxicity associated with zoledronic acid
- **8.** Opposes the action of parathyroid hormone and inhibits the activity of osteoclasts which results in an increase in bone strength
- **9.** This medication inhibits osteoclasts; osteoclasts breakdown bone to help pull calcium into the bloodstream
- **14.** A value of -2.5 or lower is indicative of osteoporosis with this assessment
- **15.** Nasal spray that can help with osteoporosis and compression fracture pain

- **17.** Important supplement to consider in osteoporotic patients
- **18.** Rare adverse effect of bisphosphonates that affects the jaw
- **19.** This form of calcium is better absorbed than carbonate
- **20.** Twice yearly injection that can cause low calcium and muscle pain as adverse effects